Fusion Antibodies (LON:FAB) Trading Down 6.5% – What’s Next?

Fusion Antibodies plc (LON:FAB) shares fell 6.5% on Wednesday . The company traded as low as GBX 11.22 and last traded at GBX 11.22. 221,346 shares were traded during trading, a decline of 51% from the average daily volume of 455,159 shares. The stock had previously closed at GBX 12.

Fusion Antibodies Trading Down 6.5%

The stock has a market capitalization of £14.03 million, a PE ratio of -7.48 and a beta of 1.22. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42. The stock has a 50 day moving average price of GBX 13.10 and a 200-day moving average price of GBX 13.68.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.